Outlook Therapeutics, Inc.
OTLK
$2.70
-$0.27-9.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 260.58% | -- | 113.28% | 153.29% | -98.67% |
| Gross Profit | 760.72% | -- | -113.28% | -153.29% | 98.67% |
| SG&A Expenses | 15.77% | 47.02% | 106.20% | 37.78% | 18.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.80% | -34.57% | 109.31% | 83.62% | 7.83% |
| Operating Income | 19.50% | 34.57% | -109.31% | -83.62% | -7.83% |
| Income Before Tax | -145.38% | 59.44% | 255.46% | 143.81% | 314.80% |
| Income Tax Expenses | -- | 0.00% | -- | -- | -- |
| Earnings from Continuing Operations | -145.38% | 59.44% | 255.46% | 143.81% | 314.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -145.38% | 59.44% | 255.46% | 143.81% | 314.80% |
| EBIT | 19.50% | 34.57% | -109.31% | -83.62% | -7.83% |
| EBITDA | 19.53% | 34.63% | -109.60% | -83.56% | -7.74% |
| EPS Basic | -128.52% | 81.25% | 183.48% | 124.01% | 218.78% |
| Normalized Basic EPS | -130.41% | 61.89% | 198.49% | 127.97% | 214.69% |
| EPS Diluted | 37.85% | 81.25% | 183.38% | 124.01% | 45.03% |
| Normalized Diluted EPS | -133.36% | 61.89% | 198.49% | 127.97% | 204.56% |
| Average Basic Shares Outstanding | 59.11% | 116.35% | 86.23% | 82.47% | 80.84% |
| Average Diluted Shares Outstanding | 45.06% | 116.35% | 86.23% | 82.47% | 98.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |